China's Leading Vaccine Developer Sinovac Sees Earnings Sink Into The Red As Scandals Rock Public Confidence
This article was originally published in PharmAsia News
Executive Summary
BEIJING - A series of vaccine scandals across China, and resulting public fear over all forms of inoculations, has caused the country's leading vaccine developer, Sinovac Biotech, to post a loss for the third quarter of this year
You may also be interested in...
Bill Gates Meets With Sinovac Scientists In Beijing: Will They Be Integrated Into Gates Foundation's Global Immunization Drives?
BEIJING - During a whirlwind tour of China, Microsoft founder Bill Gates met with scientists at China's leading vaccine developer, Sinovac Biotech, as the Gates Foundation ramps up a project to supply vaccines to kids in need across the planet
Hit Collaterally By Popular Backlash Following Vaccine Scandals, China's Sinovac Could Exploit High Quality Standards To Emerge As Winner
BEIJING - Despite being hit by a succession of vaccine scandals and resulting public fears of domestically produced biologics, China's leading vaccine developer could ultimately emerge as a more powerful player due to its sterling reputation in a field of tarnished competitors
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).